EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Psilocybin in Older Adults: Therapeutic Opportunities in Inflammation-Driven Disorders of Aging—From Depression to Neurodegeneration

Marta Jóźwiak-Bębenista iD, Anna Stasiak iD, Monika Sienkiewicz iD, Paweł Kwiatkowski iD, Edward Kowalczyk iD

International Journal of Molecular Sciences · 09.05.2026 · 27 (10) · 4229

DOI: 10.3390/ijms27104229 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 09.05.2026. Verfasst von Marta Jóźwiak-Bębenista und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, Medical University of Lodz, Zeligowskiego 7/9, 90-752 Lodz, Poland. Hauptthemen laut MEDLINE: Aging, Inflammation, Neurodegenerative Diseases, Depression. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Lodz.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aging is associated with chronic, low-grade inflammation (“inflammaging”), which contributes to neuropsychiatric and neurodegenerative disorders such as depression, Alzheimer’s disease, and Parkinson’s disease. Conventional pharmacotherapies often provide limited benefit in older adults and are further complicated by polypharmacy and drug–drug interactions. Psilocybin, a serotonergic psychedelic acting primarily as a partial agonist at the 5-HT2A receptor and currently undergoing accelerated clinical development, has emerged as a potential multimodal therapeutic agent addressing these challenges. Acting via its active metabolite psilocin, 5-HT2A receptor-mediated signaling modulates cortical glutamatergic transmission, enhances tropomyosin receptor kinase B/brain-derived neurotrophic factor (TrkB/BDNF) pathways, and modulates neuroimmune cascades (includingnuclear factor kappa B (NF-κB), with convergent systems-level effects such as reorganization of the default mode network. Human studies report acute reductions in TNF-α with variable effects on IL-6 and CRP, consistent with an immunomodulatory profile. Pharmacokinetically, psilocybin shows properties advantageous in geriatric care: rapid onset, short half-life, and predominant phase-II glucuronidation, reducing interaction risk. Controlled studies demonstrate rapid antidepressant and anxiolytic effects in major depressive disorder, treatment-resistant depression, and existential distress, with emerging feasibility signals in neurodegeneration. Together, these findings support the hypothesis that a time-limited, mechanism-based intervention may improve mood and cognition while attenuating inflammation. This review integrates current evidence on psilocybin’s neuroimmune and pharmacokinetic mechanisms relevant to aging, outlining its potential role in inflammation-related disorders and highlighting the need for targeted studies in older adults, who remain underrepresented in psychedelic research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AgingInflammationNeurodegenerative DiseasesDepressionPsilocybinHallucinogensHumansAnimalsAged

Stichwörter der Autor:innen

5-HT2Aageddepressioninflammationneurodegenerative diseasesneuronal plasticitypsilocybinreceptorserotonin

Substanzen

PsilocybinHallucinogens

Autor:innen und Institutionen

  • Department of Pharmacology and Toxicology, Medical University of Lodz, Zeligowskiego 7/9, 90-752 Lodz, Poland.
  • Department of Hormone Biochemistry, Medical University of Lodz, Zeligowskiego 7/9, 90-752 Lodz, Poland.
  • Department of Pharmaceutical Microbiology and Microbiological Diagnostic, Medical University of Lodz, Muszynskiego 1, 90-151 Lodz, Poland.
  • Department of Diagnostic Immunology, Pomeranian Medical University in Szczecin, Powstańców Wielkopolskich 72, 70-111 Szczecin, Poland.

ORCID-Profile: Marta Jóźwiak-Bębenista, Anna Stasiak, Monika Sienkiewicz, Paweł Kwiatkowski, Edward Kowalczyk

Förderung

  • Medical University of Lodz

Zitieren

APA

Jóźwiak-Bębenista, M., Stasiak, A., Sienkiewicz, M., Kwiatkowski, P., & Kowalczyk, E. (2026). Psilocybin in Older Adults: Therapeutic Opportunities in Inflammation-Driven Disorders of Aging—From Depression to Neurodegeneration. International Journal of Molecular Sciences, 27(10), 4229. https://doi.org/10.3390/ijms27104229

Vancouver

Jóźwiak-Bębenista M, Stasiak A, Sienkiewicz M, Kwiatkowski P, Kowalczyk E. Psilocybin in Older Adults: Therapeutic Opportunities in Inflammation-Driven Disorders of Aging—From Depression to Neurodegeneration. International Journal of Molecular Sciences. 2026;27(10):4229. doi:10.3390/ijms27104229

BibTeX
@article{JwiakBbenista2026,
  author = {Jóźwiak-Bębenista, Marta and Stasiak, Anna and Sienkiewicz, Monika and Kwiatkowski, Paweł and Kowalczyk, Edward},
  title = {Psilocybin in Older Adults: Therapeutic Opportunities in Inflammation-Driven Disorders of Aging—From Depression to Neurodegeneration},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {10},
  pages = {4229},
  doi = {10.3390/ijms27104229}
}
Kostenlos starten →